JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264694

Human ZNF622 (ZPR9) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ZNF622 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 1 and 1 bp deletion in exon 1 and 1 bp insertion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.

View Alternative Names

MGC108936, ZN622_HUMAN, ZNF622, Zfp622, Zinc finger protein 622, Zinc finger-like protein 9

3 Images
Sanger Sequencing - Human ZNF622 (ZPR9) knockout HeLa cell line (AB264694)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZNF622 (ZPR9) knockout HeLa cell line (AB264694)

Allele-3 : 1 bp insertion in exon 1.

Sanger Sequencing - Human ZNF622 (ZPR9) knockout HeLa cell line (AB264694)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZNF622 (ZPR9) knockout HeLa cell line (AB264694)

Allele-2 : 1 bp deletion in exon 1.

Sanger Sequencing - Human ZNF622 (ZPR9) knockout HeLa cell line (AB264694)
  • Sanger seq

Unknown

Sanger Sequencing - Human ZNF622 (ZPR9) knockout HeLa cell line (AB264694)

Allele-1 : 16 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon 1 and 1 bp deletion in exon 1 and 1 bp insertion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264694-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB264694-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264694 Human ZNF622 (ZPR9) knockout HeLa cell line", "number":"AB264694-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264694-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB264694-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264694 Human ZNF622 (ZPR9) knockout HeLa cell line", "number":"AB264694-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264694-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264694 Human ZNF622 (ZPR9) knockout HeLa cell line", "number":"AB264694-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264694-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264694 Human ZNF622 (ZPR9) knockout HeLa cell line", "number":"AB264694-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ZNF622
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ZPR9 also known as Zinc Finger Protein of Unknown Function 9 is a nuclear protein with a molecular mass of approximately 60 kDa. It contains zinc finger domains which serve as key structural motifs for binding to DNA. ZPR9 is expressed in various tissues including liver and brain but shows a higher expression in immune cells. It functions through specific DNA interactions regulating the transcriptional activity of several genes involved in cell growth and immune response.
Biological function summary

ZPR9 plays a role in managing cellular processes that include transcriptional regulation and cellular signaling. It often associates with other proteins to form complexes that modulate gene expression in response to external stimuli. Research has shown that ZPR9 interacts with components of the transcription machinery influencing numerous biological functions that encompass immune system modulation and cell cycle progression.

Pathways

ZPR9 contributes significantly to the MAPK signaling pathway and NF-kB pathway. In the MAPK pathway it connects with proteins such as ERK1/2 impacting cellular responses like proliferation and differentiation. In the NF-kB pathway ZPR9 has links with protein p65 contributing to the regulation of immune responses and inflammation. These connections indicate its integration in key signaling networks vital for cellular homeostasis and immune regulation.

ZPR9 correlates with autoimmune diseases and cancer. Its abnormally high expression in conditions like rheumatoid arthritis suggests roles in inflammatory processes. Moreover alterations in ZPR9 expression have association with cancer development where it may impact tumor growth and metastasis. In autoimmune conditions it interacts with other proteins including NF-kB showing its influence on inflammatory pathways and potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com